KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Prepaid Assets (2016 - 2025)

Arbutus Biopharma's Prepaid Assets history spans 15 years, with the latest figure at $2.8 million for Q3 2025.

  • For Q3 2025, Prepaid Assets fell 16.0% year-over-year to $2.8 million; the TTM value through Sep 2025 reached $2.8 million, down 16.0%, while the annual FY2024 figure was $2.3 million, 46.23% down from the prior year.
  • Prepaid Assets for Q3 2025 was $2.8 million at Arbutus Biopharma, down from $4.0 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $5.6 million in Q2 2022 and bottomed at $2.3 million in Q4 2024.
  • The 5-year median for Prepaid Assets is $4.1 million (2021), against an average of $3.9 million.
  • The largest annual shift saw Prepaid Assets surged 85.74% in 2021 before it plummeted 46.23% in 2024.
  • A 5-year view of Prepaid Assets shows it stood at $4.4 million in 2021, then tumbled by 35.34% to $2.9 million in 2022, then surged by 47.81% to $4.2 million in 2023, then plummeted by 46.23% to $2.3 million in 2024, then grew by 24.12% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Prepaid Assets are $2.8 million (Q3 2025), $4.0 million (Q2 2025), and $2.9 million (Q1 2025).